vTv Therapeutics Q1 net loss narrows to $4.5M; cash rises to $18.8M; FDA agrees on pediatric study plan for TTP399

vTv Therapeutics Inc.

Net loss attributable to vTv shareholders was $4.5M ($0.06/share) vs $7.0M ($0.10/share) in Q1 2022.
Cash and cash equivalents totaled $18.8M as of March 31, 2023, up from $12.1M at year-end 2022, after receiving $12M from G42 Investments.
R&D expenses increased to $3.9M from $3.1M YoY, driven by TTP399 development costs; G&A expenses decreased to $3.5M from $5.3M.
FDA agreed with pediatric study plan for TTP399 in type 1 diabetes patients aged 2-16; phase 2 study in type 2 diabetes on insulin therapy being prepared with G42 affiliate.
Revenue was $0 in Q1 2023 vs $2M in Q1 2022 (prior collaboration revenue ended).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

vTv Therapeutics Inc. reported the first quarter ended March 31, 2023 results: net income $4.5 million, EPS $0.06 per basic share.

Period: the first quarter ended March 31, 2023
Net income: $4.5 million
EPS: $0.06 per basic share
Result: reported results

Exact text from the filing

Net loss attributable to vTv shareholders for the three months ended March 31, 2023, was $4.5 million or $0.06 per basic share.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-23-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.